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license (http://creativeformed using cerebrospinal fluid (CSF) as the biomarker source. CSF has the advantage of being
closer to the brain than serum or plasma with a relative enrichment of CNS-specific proteins that
are present at very low concentrations in the blood and thus difficult to reliably quantify using stan-
dard immunochemical technologies. Recent technical breakthroughs in the field of ultrasensitive as-
says have started to change this. Here, we review the most established ultrasensitive quantitative
technologies that are currently available to general biomarker laboratories and discuss their use in
research on biomarkers for CNS disorders.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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The goal of biomarker research is to provide objective tools
that can be used for example in the clinical diagnostic work-
up, as inclusion criteria in clinical trials to enrich for patients
with a certain type of pathology and to monitor treatment ef-
fects. In the search for biomarkers, it is assumed that the
chance of finding good candidates is associated with the prox-
imity to the origin of the disease. In diseases of the central ner-
vous system (CNS), this would suggest that biopsies of the
brain or spinal cord would be the ideal specimen to investi-
gate. By its nature, however, this is almost without exception
not possible due to the invasiveness of the procedure. Instead,
analysis of cerebrospinal fluid (CSF) has been regarded a
mirror of the metabolism or pathophysiological changes in
the CNS. However, a lumbar puncture is needed to obtainco-founders of Brain Biomarker Solutions in Gothen-
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commons.org/licenses/by-nc-nd/4.0/).CSF, and this technique is sometimes considered as an inva-
sive procedure and might also give adverse events in the
form of post-lumbar puncture headache. Therefore, a Holy
Grail of biomarkers for CNS-related diseases would be to
measure them in blood, which is more easily accessible.
A proteomic approach using mass spectrometry (MS) is
often used in the search for biomarkers, and for small mole-
cules such as amino acids and lipids,MS is also used in clinical
routine settings [1]. The advantage of the method is that it
directly measures the molecule of interest but on the downside
are low throughput and an inability to measure intact larger
proteins compared to immunoassays. As the name implies, im-
munoassays use antibodies to quantify a substance in a sample.
A common technique is the sandwich enzyme-linked immuno-
sorbent assay (ELISA) in which most often the analyte is
captured between two antibodies in a sandwich-like complex
and one of the antibodies carry a signal generator, that is, an
enzyme which converts a substrate into a detectable form
(colored, fluorescent, or luminescent products) which in com-
bination with a calibrator curve allows for quantification of the
analyte of interest. ELISA is a theme with many variationsimer’s Association. This is an open access article under the CC BY-NC-ND
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be exchanged with for example a fluorophore or a DNA-based
system. In a recently described technology, ELISA has been
combined with MS-based quantification of the enzymatic
products. The technology is called enzyme-linked immuno
mass spectrometric assay andmay provide increased analytical
sensitivity, as compared to regular ELISA, by reducing the
background [2]. Immunochemical assays may also be multi-
plexed in different ELISA-like formats. Such biomarker panels
are frequently examined in the current biomarker literature
with focus on CNS disorders [3,4]. A downside with
multiplexing, however, is that it may be hard to optimize the
analytical conditions for several antigen-antibody interactions,
especially if their concentrations or biochemical characteristics
substantially differ, as compared to optimizing assays that
focus on the accurate measurement of a single analyte.
There are several issues, both biological and technical,
with the search for CNS-related biomarkers in blood. First,
a biomarker that has its origin in the CNS has to cross the
blood-brain barrier to be detected in the periphery and if
the concentration is low in CSF then it will be even lower
in the blood due to the blood:CSF volume ratio causing a
substantial dilution. Second, if the biomarker is not specific
for the CNS but also produced in the periphery, then the
contribution from CNS will potentially drown in the high
biological background caused by non-CNS sources (a good
tool to assess the risk for this is the publicly available web-
based Human Protein Atlas, http://www.proteinatlas.org/,
which presents protein expression in 44 different human tis-
sues of close to 20,000 proteins [5]). Third, the huge amount
of other proteins in blood (e.g., albumin, immunoglobulins)
introduces analytical challenges due to possible interference.
Fourth, heterophilic antibodies may be present in blood at
high concentrations that may give interference in sandwich
immunoassays. Fifth, the analyte of interest may undergo
proteolytic degradation by various proteases in plasma.
The technical issues aremainly a question of sensitivity and
antibody specificity. Ideally, the enzyme reaction that is the
final step in an ELISA should be able to increase the sensitivity
by simply extending the reaction time. However, the substrates
used are inherently unstable and therefore produce signal
even in the absence of enzyme. This leads to a technical back-
ground signal that can mask the signal caused by the sandwich
complex making quantification difficult at low concentrations.
The ability of the sandwich complex to correctly represent the
concentration of the biomarker in a sample strongly depends
on the quality of the antibodies used. If the antibodies cross-
react with other substances then a signal can be measured
even in the absence of the biomarker toward which the assay
was developed. As the blood is much denser in protein con-
tent than is CSF the risk for this is higher in the former.
The biological issues are refractory but the technical ones
can be addressed. The production of antibodies is sometimes
described as science, art, and magic, and by its nature, some
luck is needed to produce high-quality monoclonal anti-
bodies. For the problem with background, however, thereare solutions and this is what the ultrasensitive technologies
have found different ways of solving.
In this overview article, we focus on describing and dis-
cussing currently available ultrasensitive technologies that
may be useful for measuring CNS-specific or enriched pro-
teins at low concentrations in the bloodstream.2. Platforms
Most of the different methods described below build on
the sandwich principle for antibody-based quantification
discussed above and differ primarily in the method for detec-
tion. A brief description of each method is given, and further
details can be found in the cited publications. In general, the
technologies used are proprietary with the platforms avail-
able from only one company. Examples where the platforms
have been used in the field of CNS disorders are also given.
2.1. Single-molecule array
Single-molecule array (Simoa) is a digital ELISA that has
been invented and commercialized by Quanterix (www.
quanterix.com) [6]. After the formation of the sandwich com-
plexonmagneticmicrobeads, theseare transferred, in substrate
solution, to an array of 300,000 micro wells. These wells can
accommodate only one bead each and, after the addition of a
fluorogenic substrate for the enzyme with which the detection
antibody is labeled, an oil film is then applied to seal the wells
confining the reaction volume to 50 fL. This small volume al-
lows for a readable signal to be detected even if only one sand-
wich complex is present on the bead. As reporters, the enzyme
b-galactosidase and the substrate resorufin-b-D-galactopyra-
noside are used and the wells having a fluorescent signal are
counted as are all the wells containing a bead. The ratio be-
tween these counts provides the output average enzyme per
bead (AEB) number. When the AEB is low (,0.1), Poisson
statistics shows that either a bead has only one or none sand-
wich complex on its surface, hence the name digital ELISA.
When the AEB signal gets higher, increasing the probability
of more than one complex per bead, there is a transition to
the utilization of also the light intensity which allows for a
usable AEB even at signals.0.1. The algorithm for the transi-
tion is implemented in the software that comes with the fully
automated Simoa instrument to which samples and calibrators
can be fed either using a 96-well microtiter plate or vials.
2.2. Single-molecule counting
In the single-molecule counting (SMC) platform, the sand-
wich complexes, originating either from beads or plates, are
broken up and only the fluorescently labeled (Alexa Fluor)
detection antibody is drawn into a capillary tube and counted
one by one as they pass a laser beam that excites the fluoro-
phore. A digital event is counted if the fluorescence reaches
above the threshold of the background. At higher concentra-
tions, it is difficult to separate all events and a switch is made
to use the total sum of all emitted photons as readout for the
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ogy is proprietary to Singulex (www.singulex.com).
2.3. Proximity extension assay
The polymerase chain reaction (PCR) revolutionized the
field of molecular biology by allowing for a single copy of
double-stranded DNA to be amplifiedmany orders of magni-
tude. This amplifying property of PCR can also be used as
signal generator in immunochemical assays. The first pilot
assay of relevance to CNS diseases exploiting this approach
was the so-called bio-barcode assay for Ab oligomers or am-
yloid-b-derived diffusable ligands (ADDLs) [7], in which
ADDLs were captured in a sandwich between antibody-
coated magnetic particles and antibody-coated nanoparticles
modified with double-stranded DNA molecules that could
then be isolated, released, and amplified to generate a signal.
Using this approach, a marked increase in the assay signal
for ADDLs was found in autopsy ADCSF [7], but the results
have been hard to replicate, and there have been no follow-
up publications using this method.
In proximity extension assay (PEA), partly overlapping
complementary DNA strands are attached to the different
antibodies allowing the strands to hybridize if they are in
close proximity [8,9]. After addition of DNA polymerase
and deoxynucleotides, a double-stranded PCR template is
formed which can be converted to a signal using quantitative
real-time PCR. The company Olink (www.olink.com) has a
fee-for-service option using PEA, but it is possible to use the
technology elsewhere.
2.4. MagQu
The magnetic susceptibility is a physical property that the
companyMagQu (www.magqu.com) has built their technol-
ogy around. Magnetic nanoparticles are coated with an anti-
body, and on binding of the analyte, the oscillation of the
particles in an alternating magnetic field is decreased in a
concentration-dependent manner, an effect named immuno-
magnetic reduction (IMR) [10]. Unlike the other assay prin-
ciples described above, only one antibody is needed for a
signal to be generated.
2.5. Utilization of ultrasensitive technologies in the CNS
blood biomarker field
In Alzheimer’s disease (AD), the two neuropathological
hallmarks are extracellular plaques and intracellular tangles
consisting of the amyloid b (Ab) peptide and hyperphosphory-
lated tau protein (p-tau), respectively [11]. Together with total
tau (T-tau), these are now firmly established CSF biomarkers
for AD [12] and a part of the research diagnostic criteria for
the disease [13]. For Ab, the plasma concentration can be
measured without the need of ultrasensitive methods but
have been found not to correlate with the CSF concentrations,
probably due to high extracerebral contributions of Ab to
plasma, and consequently, plasma Ab does not seem to workas a biomarker for AD [12,14]. However, both Ab and T-tau
in serum, measured using Simoa, are elevated in a time-
dependent manner following resuscitation after cardiac arrest,
and T-tau also seems to predict neurological outcome [15,16],
which is in line with the observation that hypoxia in the brain
seems to be a risk factor for AD [17]. T-tau was also found to
be mildly increased in plasma in AD compared with both sub-
jects withmild cognitive impairment and healthy controls [18].
In this study, there was a substantial overlap between the
groups, making the authors to conclude that plasma T-tau is
not useful in a clinical setting. However, a better separation be-
tween AD and controls was achieved, when plasma T-tau was
assayed using IMR [19]. More studies are needed to better un-
derstand the usefulness of plasma T-tau in relation to AD.
Traumatic brain injury (TBI) is caused by external phys-
ical force, and apart from accidents, it is also a common
consequence of some sports, for example, boxing, ice hockey,
and American football. Even at repeated minor head trauma,
exemplified by Olympic boxers, T-tau in plasma is elevated
compared to controls indicative of axonal injury [20]. The
same is true for ice hockey players that had a concussion dur-
ing play [21] and for military personnel who sustained TBI
during deployment [22]. In contrast to tau, neurofilament light
(NFL), which is a marker of damage on the large caliber
myelinated axons, shows a good correlation between CSF
and blood when using a commercial assay for CSF and the
same antibody pair and calibrator on the Simoa platform for
blood (plasma or serum) [23,24]. NFL is elevated in CSF in
boxers after bout where it seems to normalize given enough
time of rest from match and training [25] and in American
football players, the serum concentration rises over the course
of a season in the players who were starters, defined as ath-
letes known to go out with the first or second team, first or sec-
ond on the depth roster, and take a majority of the repetitions,
whereas no increase was observed in the nonstarters [26].
Plasma NFL seems to be a biomarker with multiple utility
because it is increased also in subjects with progressive supra-
nuclear palsy [27] and in HIV-associated dementia [24].
The PEA has been used in the search for risk markers for
ischemic stroke, where 85 analytes were analyzed in plasma
in a targeted proteomic approach [28]. A strength of this study
was that it contained two large independent cohorts, which
mitigates the risk of false discoveries due to multiple testing.
Three proteins (N-terminal pro-B-type natriuretic peptide,
adrenomedullin, and eosinophil cationic protein) were found
to be related to ischemic stroke in both cohorts [28].
Although the focus of the present overview is on blood
markers, it is worth mentioning that ultrasensitive methods
are also useful in CSF whenever the concentration of the an-
alyte of interest is too low to be quantified using conven-
tional methods. For example, using SMC, visinin-like
protein-1 in CSF has been shown to be increased in AD
[29], associated with clinical disease progression [30] and
predictive of brain atrophy rates [31]. Also using SMC, Ab
oligomers in CSF were, compared to controls, increased in
mild cognitive impairment subjects but not in AD [32],
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form of huntingtin which causes Huntington’s disease [33].
2.6. Summary
There are presently several different methods that allow for
quantification of proteins and peptides in the subfemtomolar
range, which allows for the investigation of hypotheses that
were previously not possible to test due to the relatively low
analytical sensitivity of conventional methods. Although the
ultrasensitive methods have not yet revolutionized the CNS
blood biomarker field, the future looks promising and more
new biomarkers can be expected as the awareness and avail-
ability of the platforms will increase. Compared to CSF, blood
is further from the origin of the affected organ and also much
denser in protein content which makes method development a
challenge with regard to specificity and matrix effects, not to
mention the risk of interference by heterophilic antibodies.
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1. Systematic review: We searched PubMed for English
language articles on ultrasensitive measurement tech-
nologies for biomarker research on central nervous sys-
tem (CNS) disorders using the keywords “biomarker”
and “ultrasensitive” or “digital” or “high-sensitivity”
or “sensitive”, alone or together with other keywords
including: “Alzheimer’s”, “traumatic brain injury”,
“neurodegenerative disease”, “CNS”, “plasma”,
“serum”, “blood”, “CSF”, and several other keywords
relevant to every section. We largely selected publica-
tions fromthepast 5yearsbut didnot exclude important
older publications. Selection criteria also included a
judgment on the novelty of studies and their relevance
for clinical biomarker research for CNS disorders.
2. Interpretation: Our findings suggest that currently
available ultrasensitive technologies of relevance to
clinical biomarker research on CNS disorders produce
promising pilot results. All methods rely on antibody-
based detection and quantification, but the specific
method for quantification differs between the methods.
3. Future directions: The data so far are promising, and
the field is expected to grow substantially during the
next few years.References
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